Clinical trials: Acute Myeloid Leukemia, in Relapse, open to volunteers
Leukemia, Acute Leukemia
A Study of Revumenib and Mezigdomide in People With Leukemia
The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
- Conditions
- Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia
- Trial name
- NCT07356154
- Testing
- Revumenib, Mezigdomide
- Where
- 10 sites in United States
- Volunteers
- 52 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
The purpose of this study is to find out whether CD371-YSNVZ-IL18 CAR T cells are safe, and to look for the highest dose of CD371-YSNVZ-IL18 CAR T cells that cause few or mild side effects in participants.
- Conditions
- Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Trial name
- NCT06017258
- Testing
- CD371-specific/YSNVz/I-18 CAR T cells
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
The Allo-RevCAR01-T-CD123 drug is a combination of a cellular component (Allo-RevCAR01-T) with a recombinant antibody derivative (R-TM123), which together form the active drug.
- Trial name
- RevSTAR-123 (NCT05949125)
- Testing
- Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123
- Where
- 15 sites in Germany, Netherlands
- Volunteers
- 37 people
- Sponsor
- AvenCell Europe GmbH
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
This is an observational (non-interventional), prospective, cohort study that will collects data from patients diagnosed with relapsed or refractory acute myeloid leukemia afferent to the participanting clinical sites
- Trial name
- IMPACT STREAM (NCT06459024)
- Testing
- Registration into the STREAM platform
- Where
- 40 sites in Germany, Italy and 4 more
- Volunteers
- 4,000 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Acute Myeloid Leukemia, Relapse/Recurrence
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia.
- Trial name
- IMPACT-AML (NCT06713837)
- Testing
- High intensity therapies, Low intensity therapies
- Where
- 47 sites in Czechia, Germany and 5 more
- Volunteers
- 339 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Allogeneic HSCT, Posttransplant Complications
Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression.
- Conditions
- Allogeneic HSCT, Posttransplant Complications, GvHD, Relapse
- Trial name
- QiNKT-HSCT (NCT07570407)
- Testing
- blood draw
- Where
- Czechia
- Volunteers
- 75 people
- Sponsor
- University Hospital Pilsen
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse
A Phase I Single-arm Clinical Study of Donor NK Cells Infusion Combined With Low-dose Interleukin-2 in the Treatment of Acute Myeloid Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation.
This is a single-centre, single-arm, open-label, early clinical study to evaluate the safety, tolerability and preliminary efficacy of donor NK cells injection combined with low-dose interleukin-2 in the treatment of acute…
- Conditions
- Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Relapse, NK Cell
- Trial name
- NCT06641648
- Testing
- NK cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Peking University First Hospital
Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia
The researchers are doing this study is to find the highest dose of cytokine-induced memory-like (CIML) natural killer (NK) cells in combination with the drug atezolizumab that causes few or mild side effects in people with…
- Trial name
- NCT07011004
- Testing
- Cytokine Induced Memory-Like Natural Killer Cells, Atezolizumb, CIML-NK cell therapy
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute…
- Conditions
- Acute Myeloid Leukemia Refractory, Myelodysplastic Syndrome Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts, Acute Myeloid Leukemia, in Relapse
- Trial name
- NCT06372717
- Testing
- APL-4098, Azacitidine and APL-4098, Azacitidine and Venetoclax and APL-4098
- Where
- 9 sites in Australia, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Apollo Therapeutics Ltd
AML, Refractory/Relapse Acute Myeloid Leukemia
Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML
A Clinical Study to Investigate the Safety and Efficacy of CT0890B in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
- Trial name
- NCT07617285
- Testing
- CAR-T cells chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Peking University People's Hospital
Leukemia, Acute Myeloid Leukemia in Remission
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus…
- Conditions
- Leukemia, Acute Myeloid Leukemia in Remission, Myelodysplasia, Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT05794880
- Testing
- Magnetic-Activated Cell Sorter (CliniMACS, Miltenyi)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin
Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
The goal of this research study is to test if the combination of a new T cell therapy (dendritic cell (DC) / acute myeloid leukemia (AML) primed T cells), vaccine (DC/AML fusion vaccine) and standard of care decitabine and…
- Trial name
- NCT07374029
- Testing
- DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- David Avigan
Acute Myeloid Leukemia, Relapse/Recurrence
Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
This is a prospective, single-arm, exploratory study evaluating the combination of Bugitinib, Venetoclax, and Cytarabine in adult patients with relapsed or refractory acute myeloid leukemia (AML), excluding M3 subtype.
- Trial name
- NCT07563179
- Testing
- Bugitinib
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shenzhen University General Hospital
Leukemia, High Risk Acute Lymphoblastic Leukemia
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections.
- Conditions
- Leukemia, High Risk Acute Lymphoblastic Leukemia, High Risk Acute Myeloid Leukemia, Relapse Leukemia
- Trial name
- NCT06839456
- Testing
- Phase 1 Dose Level 1, Phase 1 Dose Level 2, Phase 1 Dose Level 3
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Children's Hospital of Philadelphia
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, Refractory, Refractory/Relapse Acute Myeloid Leukemia
- Trial name
- KNAN2001 (NCT04716452)
- Testing
- Ceramide NanoLiposome (Ceraxa)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Keystone Nano, Inc
Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
Acute myeloid leukemia Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts normal hematopoiesis, ultimately leading to bone marrow failure and death.
- Conditions
- Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)
- Trial name
- NCT07486726
- Testing
- Aclarubicin, Venetoclax, Azacitidine
- Where
- 4 sites in China
- Volunteers
- 112 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations.
- Conditions
- Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1
- Trial name
- NCT05735184
- Testing
- Ziftomenib, Venetoclax, Azacitidine
- Where
- 44 sites in United States
- Volunteers
- 420 people
- Sponsor
- Kura Oncology, Inc.
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary
Venetoclax Basket Trial for High Risk Hematologic Malignancies
This trial is evaluating the safety and tolerability of venetoclax with chemotherapy in pediatric and young adult patients with hematologic malignancies, including myelodysplastic syndrome (MDS), acute myeloid leukemia derived…
- Conditions
- Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia
- Trial name
- NCT05292664
- Testing
- Venetoclax, Azacitidine, Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Andrew E. Place, MD
Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Two key methods of GVHD prevention in allogeneic HSCT have a number of limitations: ex vivo T depletion is associated with an excess of infectious complications, and pharmacological immunosuppression with insufficient efficacy of…
- Conditions
- Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk, Acute Lymphoblastic Leukemia, Relapse
- Trial name
- NCT07366801
- Testing
- Cyclosporine A (CsA), Sirolimus, Ruxolitinib (JAKAVI®)
- Where
- Russia
- Volunteers
- 64 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Venetoclax to Augment Epigenetic Modification and Chemotherapy
The investigator is testing the addition of venetoclax to 5-azacitidine and vorinostat followed by standard chemotherapy to enhance treatment response in AML patients.
- Trial name
- NCT05317403
- Testing
- Venetoclax, Azacitadine, Vorinostat
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical College of Wisconsin